Aldo-keto reductase 1C3 may be a new radioresistance marker in non-small-cell lung cancer

Cancer Gene Therapy

Volumn 20, Issue 4, 2013, Pages 260-266

  Xie, L ^a   Yu, J ^a   Guo, W ^a   Wei, L ^a   Liu, Y ^a   Wang, X ^a   Song, X ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

AKR1C3; NSCLC; radiation therapy; radioresistance

Indexed keywords

INTERLEUKIN 6; LIPOCORTIN 5; SMALL INTERFERING RNA;

ALDO KETO REDUCTASE 1C3 GENE; APOPTOSIS; ARTICLE; CELL CYCLE; CELL SURVIVAL; CELL VIABILITY; COLONY FORMATION; CYTOTOXICITY; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; M PHASE CELL CYCLE CHECKPOINT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY;

3-HYDROXYSTEROID DEHYDROGENASES; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; INTERLEUKIN-6; LUNG NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RADIATION TOLERANCE; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL;

EID: 84876913391     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2013.15     Document Type: Article

References (33)

1. Ringborg U, Bergqvist D, Brorsson B, Cavallin-Stahl E, Ceberg J, Einhorn N et al. The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of radiotherapy for cancer including a prospective survey of radiotherapy practice in Sweden 2001-summary and conclusions. Acta Oncol 2003;42: 357-365. (Pubitemid 37193830)
2. Penning TM, Burczynski ME, Jez JM, Hung CF, Lin HK, Ma H et al. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 2000;351(Pt 1): 67-77.
3. Lin HK, Steckelbroeck S, Fung KM, Jones AN, Penning TM. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alphahydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase);immunohistochemical detection in breast and prostate. Steroids 2004;69: 795-801. (Pubitemid 39593392)
4. Penning TM, Steckelbroeck S, Bauman DR, Miller MW, Jin Y, Peehl DM et al. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors. Mol Cell Endocrinol 2006;248: 182-191.
5. Lewis MJ, Wiebe JP, Heathcote JG. Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. BMC Cancer 2004;4: 27.
6. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66: 2815-2825.
7. Xie L, Song X, Yu J, Guo W, Wei L, Liu Y et al. Solute carrier protein family may involve in radiation-induced radioresistance of non-small cell lung cancer. J Cancer Res Clin Oncol 2011;137: 1739-1747.
8. Chun JY, Nadiminty N, Dutt S, Lou W, Yang JC, Kung HJ et al. Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res 2009;15: 4815-4822.
9. Chen CC, Chen WC, Lu CH, Wang WH, Lin PY, Lee KD et al. Significance of interleukin-6 signaling in the resistance of pharyngeal cancer to irradiation and the epidermal growth factor receptor inhibitor. Int J Radiat Oncol Biol Phys 2010;76: 1214-1224.
10. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009;15: 91-102.
11. Jez JM, Flynn TG, Penning TM. A new nomenclature for the aldo-keto reductase superfamily. Biochem Pharmacol 1997;54: 639-647. (Pubitemid 27404623)
12. Hara A, Matsuura K, Tamada Y, Sato K, Miyabe Y, Deyashiki Y et al. Relationship of human liver dihydrodiol dehydrogenases to hepatic bile-acid-binding protein and an oxidoreductase of human colon cells. Biochem J 1996;313(Pt 2): 373-376. (Pubitemid 26030122)
13. Dufort I, Soucy P, Labrie F, Luu-The V. Molecular cloning of human type 3 3 alpha-hydroxysteroid dehydrogenase that differs from 20 alpha-hydroxysteroid dehydrogenase by seven amino acids. Biochem Biophys Res Commun 1996;228: 474-479. (Pubitemid 26396097)
14. Deyashiki Y, Ogasawara A, Nakayama T, Nakanishi M, Miyabe Y, Sato K et al. Molecular cloning of two human liver 3 alpha-hydroxysteroid/dihydrodiol dehydrogenase isoenzymes that are identical with chlordecone reductase and bile-acid binder. Biochem J 1994;299: (Pt 2) 545-552. (Pubitemid 24114152)
15. Khanna M, Qin KN, Wang RW, Cheng KC. Substrate specificity, gene structure, and tissue-specific distribution of multiple human 3 alpha-hydroxysteroid dehydrogenases. J Biol Chem 1995;270: 20162-20168.
16. Lin HK, Jez JM, Schlegel BP, Peehl DM, Pachter JA, Penning TM. Expression and characterization of recombinant type 2 3 alpha-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3 alpha/17 beta-HSD activity and cellular distribution. Mol Endocrinol 1997;11: 1971-1984. (Pubitemid 27524880)
17. Hyndman D, Bauman DR, Heredia VV, Penning TM. The aldo-keto reductase superfamily homepage. Chem Biol Interact 2003;143-144: 621-631.
18. Steckelbroeck S, Jin Y, Gopishetty S, Oyesanmi B, Penning TM. Human cytosolic 3alpha-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3beta-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action. J Biol Chem 2004;279: 10784-10795. (Pubitemid 38379543)
19. Rizner TL, Smuc T, Rupreht R, Sinkovec J, AKRC Penning TM. and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer. Mol Cell Endocrinol 2006;248: 126-135.
20. Ashley RA, Yu Z, Fung KM, Frimberger D, Kropp BP, Penning TM et al. Developmental evaluation of aldo-keto reductase 1C3 expression in the cryptorchid testis. Urology 2010;76: 67-72.
21. Wako K, Kawasaki T, Yamana K, Suzuki K, Jiang S, Umezu H et al. Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer. J Clin Pathol 2008;61: 448-454. (Pubitemid 351518226)
22. Penning TM, Byrns MC. Steroid hormone transforming aldo-keto reductases and cancer. Ann NY Acad Sci 2009;1155: 33-42.
23. Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly J, Dachs GU et al. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res 70: 1573-1584.
24. Bentzen SM. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer 2006;6: 702-713. (Pubitemid 44286002)
25. Wang XS, Shi Q, Williams LA, Mao L, Cleeland CS, Komaki RR et al. Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain, Behav Immun 2010;24: 968-974.
26. Simpson RJ, Hammacher A, Smith DK, Matthews JM, Ward LD. Interleukin-6: structure-function relationships. Protein Sci 1997;6: 929-955. (Pubitemid 27194135)
27. Lee SO, Lou W, Johnson CS, Trump DL, Gao AC. Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway. Prostate 2004;60: 178-186. (Pubitemid 38971829)
28. Ara T, Song L, Shimada H, Keshelava N, Russell HV, Metelitsa LS et al. Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res 2009;69: 329-337.
29. Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002;21: 7001-7010. (Pubitemid 35252974)
30. Norbury CJ, Hickson ID. Cellular responses to DNA damage. Annu Rev Pharmacol Toxicol 2001;41: 367-401. (Pubitemid 32385892)
31. Yang YC, Chao KS, Lin CP, Chen YY, Wang KL, Chen YJ. Oxaliplatin regulates DNA repair responding to ionizing radiation and enhances radiosensitivity of human cervical cancer cells. Int J Gynecol Cancer 2009;19: 782-786.
32. Sahu RP, Epperly MW, Srivastava SK. Benzyl isothiocyanate sensitizes human pancreatic cancer cells to radiation therapy. Front Biosci (Elite Ed) 2009;1: 568-576.
33. Zhuang HQ, Wang JJ, Liao AY, Wang JD, Zhao Y. The biological effect of 125I seed continuous low dose rate irradiation in CL187 cells. J Exp Clin Cancer Res 2009;28: 12.